Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Clinical applications of PET in oncology.

Rohren EM, Turkington TG, Coleman RE.

Radiology. 2004 May;231(2):305-32. Epub 2004 Mar 24. Review.

PMID:
15044750
2.

PET in oncology: will it replace the other modalities?

Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, Czernin J, Maddahi J, Phelps ME.

Semin Nucl Med. 1997 Apr;27(2):94-106. Review.

PMID:
9144854
3.

[Cost-effective PET investigations in oncology].

Kálvin B, Fekésházy A, Lengyel Z, Szakáll S Jr, Agoston P, Lengyel E, Székely J, Galuska L, Trón L, Esik O.

Magy Onkol. 2002;46(3):203-23. Epub 2002 Oct 6. Review. Hungarian.

4.

Clinical role of positron emission tomography in oncology.

Bomanji JB, Costa DC, Ell PJ.

Lancet Oncol. 2001 Mar;2(3):157-64. Review.

PMID:
11902566
5.

PET/CT in oncology: for which tumours is it the reference standard?

Collins CD.

Cancer Imaging. 2007 Oct 1;7 Spec No A:S77-87. Review.

6.

[Cost-effective PET scans in oncology].

Kálvin B, Fekésházy A, Lengyel Z, Szakáll S Jr, Agoston P, Lengyel E, Székely J, Várady E, Galuska L, Trón L, Esik O.

Orv Hetil. 2002 May 26;143(21 Suppl 3):1255-61. Review. Hungarian.

PMID:
12077909
7.

Clinical applications of (18)F-FDG in oncology.

Nabi HA, Zubeldia JM.

J Nucl Med Technol. 2002 Mar;30(1):3-9; quiz 10-1. Review.

8.

Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.

Kubota K, Matsuno S, Morioka N, Adachi S, Koizumi M, Seto H, Kojo M, Nishioka S, Nishimura M, Yamamoto H.

Ann Nucl Med. 2015 Jun;29(5):431-41. doi: 10.1007/s12149-015-0963-9. Epub 2015 Mar 27.

9.

[The role of diagnostic PET in treatment planning before tumor surgery].

Haberkorn U.

Chirurg. 2001 Sep;72(9):1010-9. Review. German.

PMID:
11594269
10.

[Current data and perspectives on positron emission tomography oncology-radiotherapy].

Lonneux M, Sibomana M, Pauwels S, Grégoire V.

Cancer Radiother. 1999 Jul-Aug;3(4):275-88. Review. French.

PMID:
10486538
11.

Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.

Facey K, Bradbury I, Laking G, Payne E.

Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267. Review.

12.
13.

Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?

Hillner BE, Tosteson AN, Song Y, Tosteson TD, Onega T, Goodman DC, Siegel BA.

J Am Coll Radiol. 2012 Jan;9(1):33-41. doi: 10.1016/j.jacr.2011.06.019.

14.

[Diagnostic value of positron emission tomography (PET) in clinical oncology].

Czech N, Brenner W, Kampen WU, Henze E.

Dtsch Med Wochenschr. 2000 May 5;125(18):565-7. Review. German. No abstract available.

PMID:
10835983
15.

[A proposal for the rational use of the PET in oncology].

Borrego Dorado I, Vázquez Albertino R.

Rev Esp Med Nucl. 2002 May;21(3):163-73. Review. Spanish.

16.
17.

[Positron-emission tomography in oncology].

Zaplatnikov K, Menzel C, Döbert N, Diehl M, Hamscho N, Grünwald F.

Klin Med (Mosk). 2003;81(12):13-21. Review. Russian.

PMID:
14971150
18.

Clinical oncologic positron emission tomography: an introduction.

Turkington TG, Coleman RE.

Semin Roentgenol. 2002 Apr;37(2):102-9. Review.

PMID:
12134363
19.

The applications of PET in clinical oncology.

Strauss LG, Conti PS.

J Nucl Med. 1991 Apr;32(4):623-48; discussion 649-50. Review.

20.

18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours.

De Maeseneer DJ, Lambert B, Surmont V, Geboes K, Rottey SW.

Acta Clin Belg. 2010 Sep-Oct;65(5):291-9.

PMID:
21128554

Supplemental Content

Support Center